USFDA completes surveillance inspection at Biocon’s API facility

30 Sep 2024 Evaluate

U.S. Food and Drug Administration (USFDA) has completed the surveillance inspection at Biocon’s API facility (Site 2), located at Bengaluru, Karnataka. USFDA had conducted the said inspection between September 23-27, 2024.

Four observations were cited at the end of the Inspection, which the Company will be addressing within the stipulated time. The Company does not foresee any impact on the business.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

372.90 0.25 (0.07%)
23-Jan-2026 10:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1630.75
Dr. Reddys Lab 1247.95
Cipla 1378.85
Zydus Lifesciences 891.55
Lupin 2155.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×